Skip to main content

Table 3 Characteristics of the study subjects according to changes in SMI over one year (N = 11,639)

From: Increase in relative skeletal muscle mass over time and its inverse association with metabolic syndrome development: a 7-year retrospective cohort study

 

Group 1

(< 0%)

(n =6525)

Group 2

(0–1%)

(n = 3734)

Group 3

(> 1%)

(n = 1380)

   

SMI 1-year increases (%)

− 0.80 (0.66)

0.43 (0.28)

1.65 (0.80)

   
 

Baseline

1-year follow up

Baseline

1-year follow up

Baseline

1-year follow up

P value*

P value†

P value‡

Age (year)

51.1 (7.9)

52.2 (7.9)

50.5 (7.8)

51.6 (7.8)

49.7 (8.0)

50.8 (8.0)

< 0.001

< 0.001

0.001

Sex (women)

2444 (37.5)

–

1724 (46.2)

–

725 (52.5)

–

< 0.001

–

–

Waist circumference (cm)

81.4 (8.2)

82.2 (8.2)

80.9 (8.6)

80.9 (8.3)

80.2 (8.6)

79.0 (8.1)

< 0.001

< 0.001

< 0.001

Body weight (kg)

64.5 (10.1)

65.2 (10.1)

63.8 (10.5)

63.4 (10.4)

63.1 (10.5)

61.4 (10.0)

< 0.001

< 0.001

< 0.001

BMI (kg/m2)

23.3 (2.5)

23.6 (2.5)

23.3 (2.6)

23.1 (2.6)

23.2 (2.7)

22.5 (2.5)

0.750

< 0.001

< 0.001

Obesity, n (%)

1527 (23.4)

1817 (27.9)

898 (24.1)

800 (21.4)

347 (25.1)

220 (15.9)

0.355

< 0.001

< 0.001

ASM (kg)

20.5 (4.2)

20.2 (4.2)

19.7 (4.3)

19.9 (4.3)

19.2 (4.3)

19.7 (4.3)

< 0.001

< 0.001

< 0.001

Fat mass (kg)

15.4 (4.4)

16.7 (4.4)

16.4 (4.5)

15.8 (4.3)

16.7 (4.5)

14.3 (4.1)

< 0.001

< 0.001

< 0.001

Percent fat mass (%)

24.0 (6.0)

25.7 (5.9)

25.7 (6.0)

25.0 (5.9)

26.6 (6.1)

23.4 (5.9)

< 0.001

< 0.001

< 0.001

SMI (%)

31.7 (3.1)

30.9 (3.1)

30.7 (3.1)

31.2 (3.1)

30.3 (3.2)

31.9 (3.2)

< 0.001

< 0.001

< 0.001

ASM/BMI (m2)

0.881 (0.155)

0.857 (0.151)

0.846 (0.153)

0.859 (0.154)

0.826 (0.156)

0.875 (0.160)

< 0.001

< 0.001

< 0.001

Hypertension, n (%)

627 (9.6)

715 (11.0)

333 (8.9)

356 (9.5)

119 (8.6)

130 (9.4)

0.345

0.037

0.035

SBP (mmHg)

113.7 (14.9)

117.8 (15.3)

114.4 (15.1)

116.0 (15.5)

114.7 (15.5)

114.4 (15.9)

0.017

< 0.001

< 0.001

DBP (mmHg)

70.3 (10.3)

74.6 (10.8)

71.0 (10.7)

73.0 (11.1)

71.0 (11.1)

71.6 (11.4)

0.001

< 0.001

< 0.001

Smoking, never/past/current, n (%)

3402/1944/1179 (52.1/29.8/18.1)

–

2209/994/531 (59.2/26.6/14.2)

–

869/319/192 (63.0/23.1/13.9)

–

< 0.001

–

–

Regular exercise, n (%)

829 (12.7)

–

573 (15.4)

–

236 (17.1)

–

< 0.001

–

–

Family history of diabetes, n (%)

590 (9.0)

–

417 (11.2)

–

156 (11.3)

–

0.001

–

–

IFG, n (%)

681 (10.4)

872 (13.4)

418 (11.2)

451 (12.1)

172 (12.5)

150 (10.9)

0.073

0.018

< 0.001

Diabetes, n (%)

–

91 (1.4)

–

32 (0.9)

–

7 (0.5)

–

0.003

–

HbA1c (%)

5.3 (0.4)

5.4 (0.4)

5.3 (0.4)

5.4 (0.4)|

5.3 (0.5)

5.4 (0.4)

0.098

0.070

< 0.001

Fasting glucose (mg/dL)

89.0 (8.7)

91.2 (9.6)

89.2 (8.7)

90.3 (9.1)

89.4 (9.4)

89.5 (8.9)

0.168

< 0.001

< 0.001

Fasting insulina (μIU/mL)

8.51 (3.38)

8.29 (3.56)

8.62 (3.41)

7.83 (3.54)

8.47 (3.60)

7.29 (3.58)

0.379

< 0.001

< 0.001

HOMA-IRa

1.89 (0.80)

1.89 (0.89)

1.92 (0.80)

1.76 (0.86)

1.90 (0.86)

1.63 (0.88)

0.249

< 0.001

< 0.001

eGFR (mL/min/1.73m2)

88.5 (12.1)

88.1 (12.6)

88.8 (12.3)

88.4 (13.1)

89.5 (13.4)

88.7 (14.2)

0.042

0.299

0.496

Total cholesterol (mg/dL)

195.0 (31.9)

199.1 (32.8)

196.9 (33.2)

197.1 (32.2)

196.0 (33.7)

193.9 (32.5)

0.018

< 0.001

< 0.001

Triglycerides (mg/dL)

110.8 (60.2)

115.0 (58.8)

114.1 (69.9)

107.9 (56.1)

109.9 (55.6)

97.8 (45.3)

0.028

< 0.001

< 0.001

HDL cholesterol (mg/dL)

58.3 (13.6)

56.4 (13.5)

58.8 (14.0)

57.5 (13.8)

59.4 (14.3)

59.3 (13.9)

0.016

< 0.001

< 0.001

LDL cholesterol (mg/dL)

123.2 (28.0)

124.2 (27.8)

124.6 (29.1)

121.2 (28.2)

123.9 (29.4)

116.5 (28.0)

0.043

< 0.001

< 0.001

C-reactive protein (mg/L)

0.11 (0.36)

0.11 (0.32)

0.11 (0.27)

0.10 (0.24)

0.10 (0.19)

0.09 (0.24)

0.144

0.069

0.125

  1. Data are presented as mean (standard deviation) or number (percent)
  2. ASM appendicular skeletal muscle mass, BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HDL high density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, IFG impaired fasting glucose, LDL low density lipoprotein, SBP systolic blood pressure, SMI skeletal muscle mass index
  3. * Analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables at baseline
  4. †Analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables at 1-year follow up
  5. ‡An ANCOVA model for comparing changes from baseline at year 1 after the adjustment for corresponding baseline values
  6. aA total of 9963 subjects and 7701 subjects were analyzed due to missing fasting insulin and HOMA-IR values at baseline and at year 1, respectively